Avidity Partners is a hedge fund manager that primarily focuses on long and short investments in the healthcare sector, utilizing fundamental, bottom-up research to identify opportunities in public and private equities globally. The firm's strategy targets sectors with high growth potential, significant innovation, and dynamic regulatory environments, including Series B investments in US-based startups across Life Sciences, Enterprise Applications, and HealthTech.
58% of their portfolio is in Biotech & Life Sciences. Deal activity decreased year-over-year (1 deals in the last 12 months vs 2 prior). Average disclosed round size is $143.8M (across 19 rounds with reported amounts).
Portfolio
19
Fund Size
—
Top Stage
Series C
Last 12 Mo
1
Team
Portfolio Breakdown
Stage Distribution
Sector Distribution
Investment Activity
Portfolio
| Company | Round | Amount | Date |
|---|---|---|---|
 Artios Pharma Limited | Series D | $115M | Nov 2025 |
 Sirona Medical | Series C | $42M | Nov 2024 |
 Aktis Oncology | Series B | $175M | Sep 2024 |
 Aledade | Growth | $260M | Jun 2023 |
 Octave | Series C | $52M | Jun 2023 |
 Quanta Therapeutics | Series D | $50.7M | May 2023 |
 UpStream Healthcare | Series B | $140M | Dec 2022 |
| NNested Therapeutics | Series A | $90M | Oct 2022 |
 Innovaccer | Series E | $150M | Dec 2021 |
| Sirona Medical | Series B | $40M | Nov 2021 |
 Exo | Series C | $220M | Jul 2021 |
| Artios Pharma Limited | Series C | $153M | Jul 2021 |
 Affinia Therapeutics | Series B | $110M | May 2021 |
 Amunix Pharmaceuticals, Inc. | Series B | $117M | Mar 2021 |
 Century Therapeutics | Series C | $160M | Mar 2021 |
 Cyteir Therapeutics | Series C | $80M | Feb 2021 |
 I-Mab | Growth | $418M | Sep 2020 |
 Athira Pharma, Inc. | Series B | $85M | Jun 2020 |
| OOruka Therapeutics | Growth | $275M | — |
Top Co-Investors
Last updated: 12 April 2026